Facebook
X
LinkedIn
ForwardReviving the Value of Radiation Therapy in Cutaneous Squamous Cell Carcinoma (cSCCa): From Early to Late Stage Disease (PRO 11)
This activity is a case-based discussion on the role of radiation therapy in the treatment of cutaneous squamous cell carcinoma. We have three academic physicians representing three different geographic locations within the United States, from the east coast, west coast and sun belt region. The activity begins with reviewing the role of definitive radiation therapy in early stage disease and how it compares with other local therapies as well as the use of newer technologies (i.e., image-guided superficial radiation therapy). Next we focus on the role of radiation in the adjuvant setting, including the role of further work up in high risk patients and when to cover elective volumes. Finally we discuss the benefit of radiation therapy in advanced stage disease as well as integrating with systemic therapies.
Target Audience
This activity is designed to meet the needs of radiation oncologists and residents.
Learning Objectives
Upon completion of this activity, the learner will be better able to:
- Explain pros and cons of different local therapies for early stage cSCCa.
- Determine appropriate work up, treatment volumes and doses of radiation therapy for adjuvant treatment of cSCCa.
- Identify the role and benefit of therapy in advanced stage disease of cSCCa.
Disclosures
• Arshin Sheybani, MD, is employed by Iowa-Wide Oncology Research Coalition NCORP
• Shauna Rosalie Campbell, DO, is employed by Cleveland Clinic.
• Lisa A. McGee, MD, is employed by Mayo Clinic.
• Jeremy P. Harris, MD, MPhil, is employed by University of California Irvine. Dr. Harris receives travel expenses and compensation from Novocure.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
Available Credit
- 1.25 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.